Nexalin Acquires PONM to Enhance HALO Clarity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Source: NASDAQ.COM
- Acquisition Overview: Nexalin Technology Inc. has acquired PONM Inc. for $1.3 million, with payment structured in tranches of Nexalin common stock, aiming to integrate AI-enabled remote monitoring and electronic health record functionalities to enhance the overall efficacy of the HALO Clarity program.
- Platform Deployment and Application: The PONM platform is already deployed at the University of California, San Diego, supporting HALO headset usage tracking and clinical research workflows, which enhances physician oversight and treatment compliance, and is expected to provide robust support for future clinical trials.
- Strategic Partnership: GreenLight Ventures has become a significant equity holder in Nexalin and established a strategic partnership to provide ongoing product, engineering, regulatory, and commercial support, ensuring the long-term success of HALO Clarity and its broader neurostimulation platform.
- Market Performance and Outlook: NXL's stock has traded between $0.31 and $2.00 over the past year, and despite a recent decline of 5.26%, the integrated platform is expected to enhance Nexalin's competitiveness and market share in the neurostimulation sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NXL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NXL
About NXL
Nexalin Technology, Inc. is a medical device company. It engaged in design and development of neurostimulation products for mental health epidemics. It has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. It also operates PONM, which is a digital health platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Australian Stock Market Shows Signs of Recovery
- Market Recovery Signs: The Australian stock market is showing signs of recovery after a significant A$45 billion downturn, with a modest 0.7% rise anticipated, indicating improved market sentiment driven by potential geopolitical resolutions and Wall Street's record highs.
- Undervalued Stock Opportunities: In the current volatile market, identifying undervalued stocks is crucial; the article explores three such opportunities on the ASX, including Navigator Global Investments, which has a market cap of approximately A$1.28 billion and is trading at A$2.6, significantly below its estimated future cash flow value of A$3.96, reflecting a 34.3% discount.
- Growth Potential of PolyNovo: PolyNovo Limited, with a market cap of A$842.83 million, is trading at A$1.22, below its estimated cash flow value of A$1.56, and is expected to see earnings grow by 37% annually, significantly outpacing the Australian market's 12% growth rate, indicating strong financial growth potential.
- Smart Parking's Financial Outlook: Smart Parking Limited, valued at A$355.10 million, is trading at A$0.86, below its estimated cash flow value of A$1.34; despite a decline in profit margins, earnings are forecasted to grow by 39.6% annually, suggesting an optimistic financial performance ahead.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
U.S. Congress Supports Nexalin's Neurostimulation Research for Veterans
- Congressional Support: The U.S. House Appropriations Committee's report language directs the VA to support research on non-invasive deep brain neurostimulation technologies, highlighting recognition of Nexalin's technology and potentially opening up more funding and market opportunities for the company.
- Funding Details: The bill allocates $945 million for VA Medical Research, emphasizing the importance of addressing traumatic brain injury (TBI) and mental health, with Nexalin's DIFS™ technology likely to benefit from this funding.
- Technology Distinction: The new report language clearly differentiates traditional stimulation devices from Nexalin's DIFS™ waveform, indicating Nexalin's unique position in the non-invasive neurostimulation field, which may facilitate its adoption in veteran healthcare.
- Clinical Research Advancement: Nexalin is accelerating its clinical research on DIFS™ technology at UC San Diego, aimed at gathering data to support its efficacy in treating TBI and PTSD, further solidifying its leadership position in the market.
See More
Nexalin Acquires PONM to Enhance HALO Clarity
- Acquisition Overview: Nexalin Technology Inc. has acquired PONM Inc. for $1.3 million, with payment structured in tranches of Nexalin common stock, aiming to integrate AI-enabled remote monitoring and electronic health record functionalities to enhance the overall efficacy of the HALO Clarity program.
- Platform Deployment and Application: The PONM platform is already deployed at the University of California, San Diego, supporting HALO headset usage tracking and clinical research workflows, which enhances physician oversight and treatment compliance, and is expected to provide robust support for future clinical trials.
- Strategic Partnership: GreenLight Ventures has become a significant equity holder in Nexalin and established a strategic partnership to provide ongoing product, engineering, regulatory, and commercial support, ensuring the long-term success of HALO Clarity and its broader neurostimulation platform.
- Market Performance and Outlook: NXL's stock has traded between $0.31 and $2.00 over the past year, and despite a recent decline of 5.26%, the integrated platform is expected to enhance Nexalin's competitiveness and market share in the neurostimulation sector.
See More
Nexalin Acquires PONM to Enhance Digital Health Platform
- Acquisition Completed: Nexalin Technology has finalized its acquisition of PONM, Inc. for a total consideration of $1.3 million, structured as stock payments tied to Nexalin's market performance, thereby enhancing the company's control in the digital health sector.
- Technological Integration Benefits: The acquisition grants Nexalin exclusive licensing of PONM's proprietary software features, including AI-integrated remote monitoring and clinical data analytics, which significantly improve the implementation efficiency and clinical research capabilities of the HALO™ Clarity program.
- Clinical Trial Preparations: The Nexalin NeuroCare™ virtual clinic has been deployed at UC San Diego to support the upcoming FDA pivotal trial involving 160 participants, with recruitment expected to begin in Q2 2026, thereby positioning Nexalin for regulatory success.
- Strategic Partnership: GreenLight Ventures has become a significant equity holder in Nexalin, establishing a strategic partnership that ensures long-term success for the HALO™ Clarity and Nexalin NeuroCare™ programs.
See More
Nexalin's Technology Significantly Improves Sleep Quality
- Clinical Study Results: Nexalin's 15 mA, 77.5 Hz stimulation method shows a statistically significant reduction in Pittsburgh Sleep Quality Index (PSQI) scores from 13.8 to 7.7 (p < 0.001) in chronic insomnia patients, while the sham group exhibited no significant change, highlighting the treatment's efficacy.
- Neuroimaging Support: The study indicates that Nexalin's DIFS™ technology not only improves sleep quality but also modulates key brain networks, providing mechanistic support that validates its non-pharmacologic treatment strategy for mental health issues.
- Innovative Technology Potential: Nexalin's high-power, non-invasive stimulation approach is considered a breakthrough in neurostimulation technology, capable of penetrating deep brain structures without being detectable by the human body, potentially advancing the standard of care for mental health significantly.
- Future Development Directions: Nexalin is advancing the HALO™ Clarity pivotal program and plans to submit a De Novo application to the FDA, with a growing body of clinical evidence suggesting broad applications of Nexalin's technology in neuropsychiatric conditions.
See More
Australian Stock Market Shows Signs of Recovery
- Market Recovery Signs: The Australian stock market is showing signs of recovery after a significant A$45 billion downturn, with a modest 0.7% rise anticipated, indicating improved market sentiment driven by potential geopolitical resolutions and Wall Street's record highs.
- Undervalued Stock Opportunities: In the current volatile market, identifying undervalued stocks is crucial; the article explores three such opportunities on the ASX, including Navigator Global Investments, which has a market cap of approximately A$1.28 billion and is trading at A$2.6, significantly below its estimated future cash flow value of A$3.96, reflecting a 34.3% discount.
- Growth Potential of PolyNovo: PolyNovo Limited, with a market cap of A$842.83 million, is trading at A$1.22, below its estimated cash flow value of A$1.56, and is expected to see earnings grow by 37% annually, significantly outpacing the Australian market's 12% growth rate, indicating strong financial growth potential.
- Smart Parking's Financial Outlook: Smart Parking Limited, valued at A$355.10 million, is trading at A$0.86, below its estimated cash flow value of A$1.34; despite a decline in profit margins, earnings are forecasted to grow by 39.6% annually, suggesting an optimistic financial performance ahead.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
U.S. Congress Supports Nexalin's Neurostimulation Research for Veterans
- Congressional Support: The U.S. House Appropriations Committee's report language directs the VA to support research on non-invasive deep brain neurostimulation technologies, highlighting recognition of Nexalin's technology and potentially opening up more funding and market opportunities for the company.
- Funding Details: The bill allocates $945 million for VA Medical Research, emphasizing the importance of addressing traumatic brain injury (TBI) and mental health, with Nexalin's DIFS™ technology likely to benefit from this funding.
- Technology Distinction: The new report language clearly differentiates traditional stimulation devices from Nexalin's DIFS™ waveform, indicating Nexalin's unique position in the non-invasive neurostimulation field, which may facilitate its adoption in veteran healthcare.
- Clinical Research Advancement: Nexalin is accelerating its clinical research on DIFS™ technology at UC San Diego, aimed at gathering data to support its efficacy in treating TBI and PTSD, further solidifying its leadership position in the market.
See More
Nexalin Acquires PONM to Enhance HALO Clarity
- Acquisition Overview: Nexalin Technology Inc. has acquired PONM Inc. for $1.3 million, with payment structured in tranches of Nexalin common stock, aiming to integrate AI-enabled remote monitoring and electronic health record functionalities to enhance the overall efficacy of the HALO Clarity program.
- Platform Deployment and Application: The PONM platform is already deployed at the University of California, San Diego, supporting HALO headset usage tracking and clinical research workflows, which enhances physician oversight and treatment compliance, and is expected to provide robust support for future clinical trials.
- Strategic Partnership: GreenLight Ventures has become a significant equity holder in Nexalin and established a strategic partnership to provide ongoing product, engineering, regulatory, and commercial support, ensuring the long-term success of HALO Clarity and its broader neurostimulation platform.
- Market Performance and Outlook: NXL's stock has traded between $0.31 and $2.00 over the past year, and despite a recent decline of 5.26%, the integrated platform is expected to enhance Nexalin's competitiveness and market share in the neurostimulation sector.
See More
Nexalin Acquires PONM to Enhance Digital Health Platform
- Acquisition Completed: Nexalin Technology has finalized its acquisition of PONM, Inc. for a total consideration of $1.3 million, structured as stock payments tied to Nexalin's market performance, thereby enhancing the company's control in the digital health sector.
- Technological Integration Benefits: The acquisition grants Nexalin exclusive licensing of PONM's proprietary software features, including AI-integrated remote monitoring and clinical data analytics, which significantly improve the implementation efficiency and clinical research capabilities of the HALO™ Clarity program.
- Clinical Trial Preparations: The Nexalin NeuroCare™ virtual clinic has been deployed at UC San Diego to support the upcoming FDA pivotal trial involving 160 participants, with recruitment expected to begin in Q2 2026, thereby positioning Nexalin for regulatory success.
- Strategic Partnership: GreenLight Ventures has become a significant equity holder in Nexalin, establishing a strategic partnership that ensures long-term success for the HALO™ Clarity and Nexalin NeuroCare™ programs.
See More
Nexalin's Technology Significantly Improves Sleep Quality
- Clinical Study Results: Nexalin's 15 mA, 77.5 Hz stimulation method shows a statistically significant reduction in Pittsburgh Sleep Quality Index (PSQI) scores from 13.8 to 7.7 (p < 0.001) in chronic insomnia patients, while the sham group exhibited no significant change, highlighting the treatment's efficacy.
- Neuroimaging Support: The study indicates that Nexalin's DIFS™ technology not only improves sleep quality but also modulates key brain networks, providing mechanistic support that validates its non-pharmacologic treatment strategy for mental health issues.
- Innovative Technology Potential: Nexalin's high-power, non-invasive stimulation approach is considered a breakthrough in neurostimulation technology, capable of penetrating deep brain structures without being detectable by the human body, potentially advancing the standard of care for mental health significantly.
- Future Development Directions: Nexalin is advancing the HALO™ Clarity pivotal program and plans to submit a De Novo application to the FDA, with a growing body of clinical evidence suggesting broad applications of Nexalin's technology in neuropsychiatric conditions.
See More
